Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 10,000 | |||
10 mg | 在庫あり | ¥ 16,000 | |||
25 mg | 在庫あり | ¥ 32,500 | |||
50 mg | 在庫あり | ¥ 52,500 | |||
100 mg | 在庫あり | ¥ 84,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,500 |
説明 | VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties. |
In vitro | VGX-1027 enhances survival rates and ameliorates clinical and histopathological signs in the NZB/NZW F1 model of systemic lupus erythematosus, thereby improving disease progression. It prevents the spontaneous development of Type 1 diabetes in NOD mice and counters the acceleration of diabetes induced either by cyclophosphamide assault or by the adoptive transfer of diabetogenic spleen cells in NOD mice. Furthermore, VGX-1027 reduces clinical symptoms of diabetes induced by MLD-STZ and inhibits pathological histological changes in the pancreas. |
In vivo | VGX-1027 exhibits inhibitory effects on the proliferation of gut bacterial antigen-reactive CD4+ CD25- T cells in vitro. It significantly suppresses the accumulation of TNF-α and nitrites induced by IL-1β/IFN-γ, and notably enhances cell survival by interfering with the toxic effects of cytokines. |
別名 | VGX1027, VGX 1027, GIT 27 |
分子量 | 205.21 |
分子式 | C11H11NO3 |
CAS No. | 6501-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.5 mg/mL (100 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VGX-1027 6501-72-0 Apoptosis Immunology/Inflammation IL Receptor TNF Interleukin Tumor Necrosis Factor Receptor VGX1027 inhibit Interleukin Related GIT27 Inhibitor TNF Receptor VGX 1027 TNFR GIT 27 GIT-27 inhibitor